A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

被引：0
|
作者：
Smare, C. [1 ]
Dave, K. [1 ]
Juarez-Garcia, A. [2 ]
Schoenherr, N. [2 ]
Abraham, P. [3 ]
Penrod, J. R. [3 ]
Camidge, D. R. [4 ]
Yuan, Y. [3 ]
机构：
[1] PAREXEL Int, London, England
[2] Bristol Myers Squibb Pharmaceut Ltd, London, England
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Univ Colorado Denver, Aurora, CO USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN236
引用
收藏
页码：S481 / S481
页数：1
相关论文
共 50 条
  • [21] Third-line chemotherapy for small cell lung cancer (SCLC)
    de Jong, W
    ten Hacken, N
    Groan, H
    [J]. LUNG CANCER, 2005, 49 : S317 - S318
  • [22] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    [J]. CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
  • [23] Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China
    Guan, Xin
    Li, Hongchao
    Xiong, Xiaomo
    Peng, Cike
    Wang, Ning
    Ma, Xiao
    Ma, Aixia
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 339 - 344
  • [24] COST-EFFECTIVENESS OF ATEZOLIZUMAB MONOTHERAPY VERSUS PEMBROLIZUMAB MONOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER
    Lin, C. W.
    Rosettie, K.
    Bilir, S. P.
    Celik, H.
    Abogunrin, S.
    Ogale, S.
    [J]. VALUE IN HEALTH, 2021, 24 : S37 - S37
  • [25] Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
    Marine, Sivignon
    Stephane, Roze
    Nicolas, Plommet
    Felizzi, Federico
    Paracha, Noman
    Benjamin, Mazaleyrat
    Perol, Maurice
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 464 - 473
  • [26] Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer
    Zhang, Longfeng
    Zeng, Xiaofang
    Cai, Hongfu
    Li, Na
    Liu, Maobai
    Qiu, Lingling
    Zheng, Bin
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (18) : 1301 - 1309
  • [27] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [28] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Gong, Jinhong
    Wan, Qian
    Shang, Jingjing
    Qian, Xiaodan
    Su, Dan
    Sun, Zhiqiang
    Liu, Guangjun
    [J]. ADVANCES IN THERAPY, 2021, 38 (10) : 5116 - 5126
  • [29] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Jinhong Gong
    Qian Wan
    Jingjing Shang
    Xiaodan Qian
    Dan Su
    Zhiqiang Sun
    Guangjun Liu
    [J]. Advances in Therapy, 2021, 38 : 5116 - 5126
  • [30] Cost-effectiveness analysis (CEA) of third-line erlotinib therapy compared to best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC)
    van der Hoek, K.
    Taylor, S. C.
    Peacock, S.
    Johnston, K.
    Melosky, B. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345